Market news

Heatmaps

Company Search

Proteome Sciences says first-quarter trading soft as expected

Wed 30 May 2018 14:12

Biomarker developer Proteome Sciences said trading so far in 2018 was 'broadly in line' with expectations amid a characteristically slow first quarter.

'As stated in our recent results, we expect 2018 to be a year of progress as we develop our biomarker services business and the market for TMT strengthens,' chief executive Jeremy Haigh said in speech notes for the company's annual general meeting.

'While the company remains cash constrained, we have had discussions with a number of our larger shareholders who remain supportive and will provide non-dilutive funding should it be required to facilitate the evolution of the business,' Haigh said.

Please be aware of the risks involved. The value of investments and any income from them, can fall as well as rise so you could get back less than you invest. Past performance is no guarantee of future performance. Tax treatment depends on your individual circunstances and may be subject to change. If in any doubt, please seek advice.